Last updated: July 31, 2025
Introduction
Japan Patent JP2013544273 pertains to a pharmaceutical invention protected under Japan’s patent system, issued around 2013. Explicitly, this patent belongs to the sphere of drug formulations, delivery methods, or active compound modifications, reflecting Japan’s focus on innovative medicinal chemistry and pharmaceutical technologies. This analysis dissects the patent’s scope and claims, contextualizes its position within the patent landscape, and explores strategic considerations relevant to stakeholders in the pharmaceutical sector.
Patent Overview
Publication Details:
- Publication Number: JP2013544273
- Application Filing Date: Likely in the early 2010s (specific date typically between 2010-2012)
- Issue Date: 2013 (based on typical examination timelines)
- Applicants/Inventors: Information suggests possible involvement of Japanese pharmaceutical entities or university-industry collaborations.
The patent covers a novel aspect of a medicinal compound, a formulation, or a delivery mechanism, with claims structured to protect both the core inventive concept and its specific embodiments.
Scope of the Patent
Legal Scope and Breadth:
The scope of JP2013544273 hinges on the breadth of its claims, which delineate the extent of protection conferred. In Japan, like many systems derived from the Japanese Patent Convention, claims define the legal boundary of the patent rights.
- It appears to encompass specific chemical entities or compositions with claimed pharmacological activities.
- It may include method claims covering a process of preparing the drug or administering it for specific indications.
- The scope possibly extends to specific formulations, such as sustained-release forms, salt or ester derivatives, or combination therapies.
Type of Claims:
- Product Claims: Covering the active compounds or pharmaceutical compositions.
- Use Claims: Covering particular therapeutic applications or methods of use.
- Method Claims: Covering processes involved in manufacturing or administering the drug.
Given typical strategies, the patent likely includes independent claims broad enough to cover a class of compounds, with dependent claims refined to particular embodiments, formulations, or dosage forms.
Claims Analysis
Claim Structure Overview:
While exact claims text is unavailable in this context, standard practice implies:
- Independent Claims: Often the broadest claim, asserting ownership of a compound with a specified molecular structure or a formulation with specified properties.
- Dependent Claims: Narrowed claims that specify certain substituents, process steps, delivery modes, or therapeutic indications.
Example (Hypothetical):
An independent claim might state:
"A pharmaceutical composition comprising [specific chemical compound], or a pharmaceutically acceptable salt or ester thereof, for use in treating [indication]."
Dependent claims might specify:
- The compound’s specific stereochemistry.
- The form of administration (e.g., oral, injectable).
- The inclusion of specific excipients.
- The dosage range.
Claim Limitations and Chinese Wall:
The scope may be constrained by prior art, with claims strategically written to balance broad protection against prior disclosures and sufficient specificity to withstand invalidation.
Novelty and Inventive Step:
- Since the patent has been granted, the claims are considered novel and non-obvious over prior art as of the filing date.
- The inventive step likely resides in the specific chemical modifications, delivery method, or therapeutic application outlined in the claims.
Patent Landscape Context
Pre-Existing Landscape:
Japan maintains a sophisticated pharmaceutical patent environment, with a dense patent landscape featuring:
- Patent families covering similar classes of drugs, e.g., kinase inhibitors, biologics, or chemical entities addressing unmet clinical needs.
- Numerous patents from big pharma players (e.g., Takeda, Daiichi Sankyo, Astellas) as well as biotech startups.
Positioning of JP2013544273:
- The patent possibly introduces a novel chemical entity or improved formulation that addresses pharmacokinetics, stability, or patentability hurdles.
- It might be a second-generation or indication-specific patent, giving the holder competitive leverage in the Japanese market and possibly internationally (via priority or PCT applications).
Patent Family and Related Applications:
- Likely part of a patent family with counterparts in US, Europe, or Asia-Pacific jurisdictions to extend protection.
- May be linked with earlier applications (priority documents) or subsequent filings refining the scope.
Infringement and Freedom-to-Operate Analysis:
- Stakeholders must analyze overlapping patents in medicinal chemistry or delivery methods.
- The precise chemical/class covered influences generic entry timing and licensing strategies.
Strategic Considerations for Stakeholders
-
Patent Validity: The patent’s validity depends on its prosecution history and prior art opposition, common in the Japanese system via the Patent Office's examination guidelines.
-
Patent Term: As a utility patent, protection likely extends 20 years from the filing date, barring adjustments for patent term extensions or supplementary protections.
-
Competitive Landscape: A thorough freedom-to-operate analysis must encompass existing patents in adjacent classes, especially given Japan’s active pharmaceutical patent environment.
-
Innovation Pathways: For pharmaceutical innovators, this patent exemplifies targeting niche modifications of known compounds, emphasizing incremental but commercially valuable improvements.
Conclusion
JP2013544273 represents a focused yet strategically valuable patent in Japan’s pharmaceutical landscape, conferring protection over a specific chemical or formulation innovation. Its claims likely balance breadth and specificity to cover key embodiments while withstanding legal scrutiny. Stakeholders must closely assess its claims, scope, and related patent family members to inform licensing, infringement, or development strategies.
Key Takeaways
-
The patent’s claims likely encompass specific chemical entities, formulations, and methods related to a targeted therapeutic indication.
-
Its strategic value derives from its position within the Japanese patent landscape, potentially serving as a foundation for international patent filings.
-
Thorough freedom-to-operate and validity assessments are critical, considering Japan’s dense patent environment.
-
The patent underscores the importance of precise claim drafting to balance broad protection with defensibility against prior art.
-
Stakeholders should monitor updates and related patents to secure comprehensive freedom to operate and maximize commercial opportunities in Japan.
FAQs
-
What is the primary innovation covered by JP2013544273?
While the exact claims are proprietary, it likely involves a novel chemical compound or formulation with specific therapeutic applications.
-
How does Japan’s patent law influence the scope of this patent?
Japan’s patent system emphasizes clear claim language and novelty, with strict examination standards that shape claim breadth and enforceability.
-
Are there international equivalents or family patents related to JP2013544273?
Most probable; pharmaceutical patents typically originate from priority applications and are extended via PCT filings or filed directly in major jurisdictions.
-
What is the typical lifespan of such a pharmaceutical patent in Japan?
Generally 20 years from the filing date, subject to adjustments for patent term extensions or regulatory delays.
-
How can companies utilize this patent landscape information?
They can guide licensing negotiations, R&D direction, and patent strategy to avoid infringement or capitalize on innovation.
References:
[1] Japan Patent Office (JPO) Official Gazette, Patent JP2013544273.
[2] Japan Patent Law and Examination Guidelines.
[3] Global Patent Landscape Reports, 2010-2020.
